DOAC in Patients with Child a or B Liver Cirrhosis

Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · May 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, apixaban (Eliquis®) and edoxaban (Lixiana®), on patients who have liver cirrhosis, specifically those classified as Child A or B. The main goal is to see how well these medications can reduce the production of thrombin, a substance in the blood that can lead to clotting. By understanding how these drugs work in patients with liver disease, researchers hope to gather information that will help design future studies to improve health outcomes for people with liver cirrhosis.

To participate in this trial, you must be at least 18 years old and have a diagnosis of liver cirrhosis classified as Child A or B. You will need to provide written consent to take part. If you join the study, you’ll be randomly assigned to receive either apixaban or edoxaban for a week. It's important to know that certain conditions, like pregnancy or severe gastrointestinal problems, may prevent you from participating. This trial is currently recruiting, so if you think you might be eligible, it could be a great opportunity to contribute to research that may help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Patient with previously diagnosed liver cirrhosis Child A or B
• • Written informed consent
• Exclusion Criteria:
• • Pregnancy
• • Oesophageal varices with grade superior to 1 or with red signs
• • Active ulcer disease of the gastrointestinal tract
• • History of haemorrhagic stroke
• • Severe uncontrolled hypertension
• • Recent brain, spinal or ophthalmic surgery
• • Kidney function inadequate for DOAC treatment
• • Concomitant treatment with anti-platelet drugs
• • Concomitant treatment with anticoagulant drugs (VKA, LMWH, DOAC)
• • Any contraindications for DOAC administration
• • Inability to give informed consent